论文部分内容阅读
目的:研究分析对小儿支原体肺炎患者给予阿奇霉素治疗的用药方案和治疗效果,为其临床治疗提供有效的理论依据。方法:回顾性分析2010年6月-2012年6月期间,我院收治的394例小儿支原体肺炎患者的临床资料,根据患儿入院治疗的不同时间以及治疗期间所接受的不同治疗方案,将394例患儿分为两组,对照组患儿204例,观察组患儿190例,两组患儿临床期间均给予常规基础治疗,其中对照组患儿在基础治疗的基础上加用红霉素静脉滴注治疗,用药剂量为20mg/kg,每日1次,观察组患儿在基础治疗的基础上给予阿奇霉素静脉滴注治疗,用药剂量为10mg/kg,每日1次,两组患儿均接受两周治疗,比较两组患儿的临床疗效和安全情况。结果:治疗后观察组患儿的临床有效率为98.9%,对照组患儿的治疗有效率为70.6%,两组比较具有明显差异,差异具有统计学意义,(P<0.05);观察组患儿的退热时间,咳嗽、啰音、X线阴影消失时间,以及患儿的住院时间明显短于对照组,组间比较差异明显,具有统计学意义,(P<0.05);观察组患儿治疗期间发生的不良反应情况明显少于对照组,两组比较差异具有明显的统计学意义,(P<0.05)。结论:对小儿支原体肺炎患者采用阿奇霉素治疗具有良好的临床疗效,住院时间短,安全性好,值得临床关注和推广。
OBJECTIVE: To study and analyze the drug regimen and therapeutic effect of azithromycin in children with mycoplasma pneumonia, and to provide an effective theoretical basis for its clinical treatment. Methods: The clinical data of 394 patients with mycoplasma pneumoniae pneumonia admitted in our hospital from June 2010 to June 2012 were retrospectively analyzed. According to the different treatment of children admitted to hospital at different times and different treatment regimens, 394 The cases were divided into two groups: 204 children in the control group and 190 children in the observation group. Both groups were given routine basic treatment during the clinical period. The children in the control group were treated with erythromycin Intravenous drip treatment, the dose of 20mg / kg, 1 day, the observation group was treated with azithromycin on the basis of intravenous infusion therapy, the dose of 10mg / kg, once daily, two groups of children All patients received two weeks of treatment. The clinical efficacy and safety of the two groups were compared. Results: After treatment, the clinical effective rate was 98.9% in the observation group and 70.6% in the control group. The difference between the two groups was statistically significant (P <0.05) Children’s fever, cough, rales, disappearance of X-ray shadow and hospitalization time of children were significantly shorter than those of the control group, with significant difference between the two groups (P <0.05); children in the observation group Adverse reactions occurred during treatment were significantly less than the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion: Azithromycin in children with mycoplasmal pneumonia has good clinical curative effect, short hospital stay, good safety and deserves clinical attention and promotion.